Webinars & Conferences
Lost your password?
Create your account
You are here
The antibiotic R&D landscape in Japan – by Norio Ohmagari
25 November 2020
Tackling the drug-resistance pandemic – 2020 and beyond – by Laura J.V. Piddock
23 November 2020
Why are new antibacterials failing as commercial products? – by Patricia A. Bradford
19 November 2020
COVID-19: Coinfection, secondary bacterial infections and AMR in India – by Venkatasubramanian Ramasubramanian
12 November 2020
Running a phase 3 trial for a new drug for gonorrhoea during the coronavirus pandemic – by Markus Heep, Esther Bettiol, Tanyaporn Wansom ...
15 October 2020
A lesson learned from COVID-19: The importance of non-inferiority (NI) trials for developing new antimicrobial agents before widespread need ...
6 October 2020
Why we need a new access model for antibiotics – by Yann Ferrisse and Fernando Pascual Martinez
1 October 2020
Moving from paper to action – The status of National AMR Action Plans in African countries – by Mirfin Mpundu
25 September 2020
Knowledge sharing for antimicrobial research: AntibioticDB and SPARK and why researchers should use them – by Jack Stone and Maria Laura ...
5 August 2020
Getting the most out of antimicrobial surveillance – by Mariana Castanheira
28 May 2020
COVID-19 and antimicrobial resistance: Are there any unknowns that will become known? – by Stephan Harbarth
13 May 2020
COVID-19 and its impact on antimicrobial stewardship – by Andrew Seaton
30 April 2020